NewAmsterdam Pharma Company N.V.
NAMS · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $772 | $340 | $468 | $60 |
| Short-Term Investments | $62 | $0 | $0 | $0 |
| Receivables | $21 | $2 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 |
| Other Curr. Assets | $8 | $4 | $10 | $7 |
| Total Curr. Assets | $863 | $347 | $478 | $67 |
| Property Plant & Equip (Net) | $1 | $0 | $0 | $0 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangibles | $1 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 |
| Tax Assets | $0 | $0 | $0 | $0 |
| Other NC Assets | $0 | $0 | $0 | $1 |
| Total NC Assets | $1 | $0 | $1 | $1 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $865 | $347 | $478 | $68 |
| Liabilities | – | – | – | – |
| Payables | $5 | $17 | $12 | $7 |
| Short-Term Debt | $0 | $0 | $0 | $0 |
| Tax Payable | $0 | $0 | $0 | $0 |
| Deferred Revenue | $6 | $9 | $0 | $0 |
| Other Curr. Liab. | $96 | $24 | $24 | $4 |
| Total Curr. Liab. | $107 | $50 | $36 | $11 |
| LT Debt | $0 | $0 | $0 | $0 |
| Deferred Rev, NC | $0 | $1 | $0 | $0 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | $0 |
| Other NC Liab. | $0 | $8 | $12 | $0 |
| Total NC Liab. | $0 | $9 | $12 | $0 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $0 | $0 | $0 | $0 |
| Total Liabilities | $107 | $59 | $48 | $11 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $13 | $10 | $10 | $0 |
| Retained Earnings | $0 | -$317 | -$140 | -$39 |
| AOCI | $4 | $4 | $4 | $1 |
| Other Equity | $740 | $591 | $556 | $95 |
| Total Equity | $758 | $288 | $430 | $57 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $865 | $347 | $478 | $68 |
| Net Debt | -$771 | -$340 | -$468 | -$60 |